113 results on '"Aceto N"'
Search Results
2. Resistance to mesenchymal reprogramming sustains clonal propagation in metastatic breast cancer
- Author
-
Saini, M., Schmidleitner, L., Moreno, H.D., Donato, E., Falcone, M., Bartsch, J.M., Vogel, V., Würth, R., Pfarr, N., Espinet, E., Lehmann, M., Königshoff, M., Reitberger, M., Haas, S., Graf, E., Schwarzmayr, T., Strom, T.M., Spaich, S., Sütterlin, M., Schneeweiss, A., Weichert, W., Schotta, G., Reichert, M., Aceto, N., Sprick, M.R., Trumpp, A., Scheel, C.H., and Klein, C.
- Subjects
Cancer Research - Abstract
The acquisition of mesenchymal traits is considered a hallmark of breast cancer progression. However, the functional relevance of epithelial-to-mesenchymal transition (EMT) remains controversial and context dependent. Here, we isolate epithelial and mesenchymal populations from human breast cancer metastatic biopsies and assess their functional potential in vivo. Strikingly, progressively decreasing epithelial cell adhesion molecule (EPCAM) levels correlate with declining disease propagation. Mechanistically, we find that persistent EPCAM expression marks epithelial clones that resist EMT induction and propagate competitively. In contrast, loss of EPCAM defines clones arrested in a mesenchymal state, with concomitant suppression of tumorigenicity and metastatic potential. This dichotomy results from distinct clonal trajectories impacting global epigenetic programs that are determined by the interplay between human ZEB1 and its target GRHL2. Collectively, our results indicate that susceptibility to irreversible EMT restrains clonal propagation, whereas resistance to mesenchymal reprogramming sustains disease spread in multiple models of human metastatic breast cancer, including patient-derived cells in vivo.
- Published
- 2023
3. Tyrosine phosphatase SHP2 increases cell motility in triple-negative breast cancer through the activation of SRC-family kinases
- Author
-
Sausgruber, N, Coissieux, M-M, Britschgi, A, Wyckoff, J, Aceto, N, Leroy, C, Stadler, M B, Voshol, H, Bonenfant, D, and Bentires-Alj, M
- Published
- 2015
- Full Text
- View/download PDF
4. Tyrosine phosphatase PTPα contributes to HER2-evoked breast tumor initiation and maintenance
- Author
-
Meyer, D S, Aceto, N, Sausgruber, N, Brinkhaus, H, Müller, U, Pallen, C J, and Bentires-Alj, M
- Published
- 2014
- Full Text
- View/download PDF
5. O07 - Development of novel prostate cancer patient-derived models and applications for translational research
- Author
-
Servant, R., Garioni, M., Vlajnic, T., Pueschel, H., Müller, D.C., Zellweger, T., Templeton, A.J., Garofoli, A., Maletti, S., Diamantopoulou, Z., Piscuoglio, S., Rubin, M.A., Aceto, N., Seifert, H., Bubendorf, L., Rentsch, C.A., and Le Magnen, C.
- Published
- 2021
- Full Text
- View/download PDF
6. Development of a continuous process to obtain a confectionery fat from tallow: Final status
- Author
-
Kozempel, M. F., Craig, J. C., Heiland, W. K., Elias, S., and Aceto, N. C.
- Published
- 1981
- Full Text
- View/download PDF
7. Technical new feature: A continuous process and cost estimate for the production of lsopropenyl stearate
- Author
-
Kozempel, M. F., Stabile, R. L., Craig, J. C., Sinnamon, H. I., and Aceto, N. C.
- Published
- 1978
- Full Text
- View/download PDF
8. 168 Receptor tyrosine kinase pathways and cell survival in mesothelioma
- Author
-
Bertino, P., Aceto, N., Barbone, D., Busacca, S., Mutti, L., and Gaudino, G.
- Published
- 2006
- Full Text
- View/download PDF
9. Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer
- Author
-
Weitsman, G., Hazra, S., Juric, D., Kim, P., Radosevic-Robin, N., Perou, C. M., Tao, J. J., Lewis, J. S., Morse, N., Elkabets, M., Maheswaran, S., Viola-Villegas, N. T., Aceto, N., Penault-Llorca, F., Bergamaschi, A., Baselga, J., Scaltriti, M., Bosch, A., Castel, P., Barber, P., Vojnovic, B., Carey, L. A., Ellis, H., Ng, T., Singh, S., and Auricchio, N.
- Subjects
body regions ,skin and connective tissue diseases ,3. Good health - Abstract
Both abundant epidermal growth factor receptor (EGFR or ErbB1) and high activity of the phosphatidyl-inositol 3-kinase (PI3K)–Akt pathway are common and therapeutically targeted in triple-negative breast cancer (TNBC). However, activation of another EGFR family member [human epidermal growth factor receptor 3 (HER3) (or ErbB3)] may limit the antitumor effects of these drugs. We found that TNBC cell lines cultured with the EGFR or HER3 ligand EGF or heregulin, respectively, and treated with either an Akt inhibitor (GDC-0068) or a PI3K inhibitor (GDC-0941) had increased abundance and phosphorylation of HER3. The phosphorylation of HER3 and EGFR in response to these treatments was reduced by the addition of a dual EGFR and HER3 inhibitor (MEHD7945A). MEHD7945A also decreased the phosphorylation (and activation) of EGFR and HER3 and the phosphorylation of downstream targets that occurred in response to the combination of EGFR ligands and PI3K-Akt pathway inhibitors. In culture, inhibition of the PI3K-Akt pathway combined with either MEHD7945A or knockdown of HER3 decreased cell proliferation compared with inhibition of the PI3K-Akt pathway alone. Combining either GDC-0068 or GDC-0941 with MEHD7945A inhibited the growth of xenografts derived from TNBC cell lines or from TNBC patient tumors, and this combination treatment was also more effective than combining either GDC-0068 or GDC-0941 with cetuximab, an EGFR-targeted antibody. After therapy with EGFR-targeted antibodies, some patients had residual tumors with increased HER3 abundance and EGFR/HER3 dimerization (an activating interaction). Thus, we propose that concomitant blockade of EGFR, HER3, and the PI3K-Akt pathway in TNBC should be investigated in the clinical setting.
10. Genome profiling of chronic myelomonocytic leukemia: frequent alterations of RAS and RUNX1 genes
- Author
-
Olschwang Sylviane, Bentires-Alj Mohamed, Sainty Danielle, Arnoulet Christine, Pinson Stephane, Houdayer Claude, Aceto Nicola, Remy Virginie, Adélaïde José, Trouplin Virginie, Gelsi-Boyer Véronique, Vey Norbert, Mozziconacci Marie-Joëlle, Birnbaum Daniel, and Chaffanet Max
- Subjects
Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Chronic myelomonocytic leukemia (CMML) is a hematological disease close to, but separate from both myeloproliferative disorders (MPD) and myelodysplastic syndromes and may show either myeloproliferative (MP-CMML) or myelodysplastic (MD-CMML) features. Not much is known about the molecular biology of this disease. Methods We studied a series of 30 CMML samples (13 MP- and 11 MD-CMMLs, and 6 acutely transformed cases) from 29 patients by using Agilent high density array-comparative genomic hybridization (aCGH) and sequencing of 12 candidate genes. Results Two-thirds of samples did not show any obvious alteration of aCGH profiles. In one-third we observed chromosome abnormalities (e.g. trisomy 8, del20q) and gain or loss of genes (e.g. NF1, RB1 and CDK6). RAS mutations were detected in 4 cases (including an uncommon codon 146 mutation in KRAS) and PTPN11 mutations in 3 cases. We detected 11 RUNX1 alterations (9 mutations and 2 rearrangements). The rearrangements were a new, cryptic inversion of chromosomal region 21q21-22 leading to break and fusion of RUNX1 to USP16. RAS and RUNX1 alterations were not mutually exclusive. RAS pathway mutations occurred in MP-CMMLs (~46%) but not in MD-CMMLs. RUNX1 alterations (mutations and cryptic rearrangement) occurred in both MP and MD classes (~38%). Conclusion We detected RAS pathway mutations and RUNX1 alterations. The latter included a new cryptic USP16-RUNX1 fusion. In some samples, two alterations coexisted already at this early chronic stage.
- Published
- 2008
- Full Text
- View/download PDF
11. Macaroni enrichment with dairy-based protein sources
- Author
-
Talley, F. B., Aceto, N. C., Sinnamon, H. I., Schoppet, E. F., and Panzer, C. C.
- Subjects
- *
FOOD , *PROTEINS - Published
- 1979
12. Continuous coagulation of cottage whey protein
- Author
-
Panzer, C. C., Aceto, N. C., Schoppet, E. F., and Sinnamon, H. I.
- Subjects
- *
PROTEINS - Published
- 1976
- Full Text
- View/download PDF
13. Enrichment of pasta with cottage cheese whey proteins
- Author
-
Talley, F. B., Aceto, N. C., Sinnamon, H. I., Schoppet, E. F., and Panzer, C. C.
- Subjects
- *
COTTAGE cheese - Published
- 1976
14. Continuous explosion-puffing of apples
- Author
-
Craig, Jr., J. C., Konstance, R. P., Aceto, N. C., and Egoville, M. J.
- Subjects
FOOD industry - Published
- 1980
15. Technical new feature.
- Author
-
Kozempel, M., Stabile, R., Craig, J., Sinnamon, H., and Aceto, N.
- Abstract
A continuous process for the commercial production of isopropenyl stearate (IPS) from triple pressed stearic acid and a stabilized form of propyne has been developed. Cost estimates, including capital costs, operating costs, and profitability, for commercial scale plant production which show the process to be economically feasible are presented. This potentially profitable process offers the advantages of reliable raw material sources, minimal external thermal requirements, and usable process waste streams. For a plant producing 5 million pounds of IPS per year, the selling price range is 80 to 107 cents/lb IPS, corresponding to a raw material cost range of 27 to 54 cents/lb of IPS. For a 20 million pound per year plant, the selling price range is 58 to 85 cents/lb IPS. The selling prices include a 20% annual return on fixed capital investment. Fixed capital requirement ranges from 2.7 to 10.9 million dollars (3rd quarter, 1975) for plants ranging in size from 5 to 50 million pounds of IPS per year, respectively. [ABSTRACT FROM AUTHOR]
- Published
- 1978
- Full Text
- View/download PDF
16. Continous explosion-puffing of potatoes
- Author
-
Sullivan, J. F., Craig, Jr., J. C., Konstance, R. P., Aceto, N. C., and Heiland, W. K.
- Subjects
FOOD preservation - Published
- 1977
- Full Text
- View/download PDF
17. A0529 - Novel patient-derived organoid xenograft models emulate molecular, functional, and clinical features of advanced prostate cancer.
- Author
-
Servant, R., Parmentier, R., Dolgos, R., Wang, J., Diamantopoulou, Z., Roma, L., Stenner, F., Templeton, A.J., Aceto, N., Bubendorf, L., Seifert, H., Rentsch, C.A., and Le Magnen, C.
- Subjects
- *
PROSTATE cancer - Published
- 2024
- Full Text
- View/download PDF
18. A0418 - Establishment and characterization of two novel patient-derived organoid xenograft models of advanced prostate cancer.
- Author
-
Servant, R., Diamantopoulou, Z., Garioni, M., Roma, L., Vlajnic, T., Templeton, A.J., Pueschel, H., Piscuoglio, S., Aceto, N., Bubendorf, L., Seifert, H., Rentsch, C.A., and Le Magnen, C.
- Subjects
- *
PROSTATE cancer - Published
- 2022
- Full Text
- View/download PDF
19. Simulating the Effect of Removing Circulating Tumor Cells (CTCs) from Blood Reveals That Only Implantable Devices Can Significantly Reduce Metastatic Burden of Patients.
- Author
-
Baumgartner W, Aceto N, and Lifka S
- Abstract
Circulating tumor cells (CTCs) are cells that have separated from a solid cancerous lesion and entered the bloodstream. They play a crucial role in driving the metastatic spread to distant organs, which is the leading cause of cancer-related deaths. Various concepts for blood purification devices aiming to remove CTCs from the blood and prevent metastases have been developed. Until now, it is not clear if such devices can indeed reduce new metastasis formation in a significant way. Here, we present a simple theoretical model of CTCs in the bloodstream that can be used to predict a reduction in metastatic burden using an extracorporeal or intracorporeal blood purification device. The model consists of a system of ordinary differential equations that was numerically solved and simulated. Various simulations with different parameter settings of extracorporeal and intracorporeal devices revealed that only devices implanted directly in tumor-draining vessels can reduce the metastatic burden significantly. Even if an extracorporeal device is used permanently, the reduction in metastases is only 82%, while a permanently operating implanted device in the tumor-draining vessel would achieve a reduction of 99.8%. These results are mainly due to the fact that only a small fraction of CTCs reaches peripheral circulation, resulting in a proportionally small amount of purified blood in extracorporeal devices.
- Published
- 2024
- Full Text
- View/download PDF
20. A Molecular Voyage: Multiomics Insights into Circulating Tumor Cells.
- Author
-
Zhang YW, Gvozdenovic A, and Aceto N
- Subjects
- Humans, Genomics methods, Proteomics methods, Biomarkers, Tumor, Single-Cell Analysis methods, Multiomics, Neoplastic Cells, Circulating metabolism, Neoplastic Cells, Circulating pathology, Neoplasms pathology, Neoplasms genetics, Neoplasms blood, Neoplasms metabolism
- Abstract
Circulating tumor cells (CTCs) play a pivotal role in metastasis, the leading cause of cancer-associated death. Recent improvements of CTC isolation tools, coupled with a steady development of multiomics technologies at single-cell resolution, have enabled an extensive exploration of CTC biology, unlocking insights into their molecular profiles. A detailed molecular portrait requires CTC interrogation across various levels encompassing genomic, epigenetic, transcriptomic, proteomic and metabolic features. Here, we review how state-of-the-art multiomics applied to CTCs are shedding light on how cancer spreads. Further, we highlight the potential implications of CTC profiling for clinical applications aimed at enhancing cancer diagnosis and treatment., Significance: Exploring the complexity of cancer progression through cutting-edge multiomics studies holds the promise of uncovering novel aspects of cancer biology and identifying therapeutic vulnerabilities to suppress metastasis., (©2024 American Association for Cancer Research.)
- Published
- 2024
- Full Text
- View/download PDF
21. Site-directed conjugation of single-stranded DNA to affinity proteins: quantifying the importance of conjugation strategy.
- Author
-
Rocha Tapia A, Abgottspon F, Nilvebrant J, Nygren PÅ, Duclos Ivetich S, Bello Hernandez AJ, Thanasi IA, Szijj PA, Sekkat G, Cuenot FM, Chudasama V, Aceto N, deMello AJ, and Richards DA
- Abstract
Affinity protein-oligonucleotide conjugates are increasingly being explored as diagnostic and therapeutic tools. Despite growing interest, these probes are typically constructed using outdated, non-selective chemistries, and little has been done to investigate how conjugation to oligonucleotides influences the function of affinity proteins. Herein, we report a novel site-selective conjugation method for furnishing affinity protein-oligonucleotide conjugates in a 93% yield within fifteen minutes. Using SPR, we explore how the choice of affinity protein, conjugation strategy, and DNA length impact target binding and reveal the deleterious effects of non-specific conjugation methods. Furthermore, we show that these adverse effects can be minimised by employing our site-selective conjugation strategy, leading to improved performance in an immuno-PCR assay. Finally, we investigate the interactions between affinity protein-oligonucleotide conjugates and live cells, demonstrating the benefits of site-selective conjugation. This work provides critical insight into the importance of conjugation strategy when constructing affinity protein-oligonucleotide conjugates., Competing Interests: There are no conflicts to declare., (This journal is © The Royal Society of Chemistry.)
- Published
- 2024
- Full Text
- View/download PDF
22. Pulmonary Tumor Thrombotic Microangiopathy in a Patient with Rapid Progressive Triple-Negative Breast Cancer.
- Author
-
Rudolf F, Baschong A, Bilecen D, Aceto N, and Vetter M
- Abstract
Introduction: Pulmonary tumor thrombotic microangiopathy (PTTM) is a rare complication of metastatic carcinoma, which occurs in patients with pulmonary arterial hypertension, and is mostly fatal. Circulating tumor cell clusters have been recognized as critical factors during breast cancer progression., Case Presentation: An 80-year-old woman with triple-negative breast cancer was admitted to our hospital with progressive dyspnea and lower back pain. Breast cancer treatment included mastectomy, neoadjuvant and adjuvant chemotherapy as well as adjuvant radiotherapy, receiving her last cycle of radiotherapy 8 days before death. At admission, D-dimers were strongly elevated and platelets were low. NT-pro-BNP was moderately elevated. A CT scan of the chest did not show pulmonary embolism but revealed interlobular septal thickening, centrilobular consolidation, and distension of the pulmonary arteries. Moreover, new skeletal and most likely lymphatic metastasis was described. Treatment with oxygen and oral glucocorticoids was initiated, assuming radiotherapy-induced pneumonitis. Due to low expression of PD-L1 and her markedly bad performance status, tumor-specific therapy was not possible, and the treatment regimen was changed to best supportive care. The patient died 8 days after admission. Autopsy revealed numerous events consistent with tumor emboli in the pulmonary vessels, suggesting PTTM., Conclusion: PTTM is a rare and mostly fatal complication in malignant breast cancer. As an early detection is difficult, further investigation is needed. Circulating tumor cluster cells may be one way to detect PTTM early and improve patients' survival., Competing Interests: Related to the present work, the authors disclose no potential conflicts of interest. The authors declare that they have no competing interests., (© 2024 The Author(s). Published by S. Karger AG, Basel.)
- Published
- 2024
- Full Text
- View/download PDF
23. Alone you go faster, together you go farther.
- Author
-
Aceto N
- Subjects
- Animals, Humans, Neoplasm Metastasis, Neoplastic Cells, Circulating pathology
- Abstract
The metastatic process is an extraordinarily complex step-by-step procedure, characterized by many analogies with migratory patterns of humans or animals across our planet. The ongoing interrogation of circulating tumor cells (CTCs), caught in the act of spreading from one location to another, is revealing distinct behaviors including biological, physical, and mechanical features that impact on their likelihood to form metastasis. In this viewpoint, I will discuss some of these findings and provide a perspective on the metastatic journey, open questions and opportunities to exploit some of the most recent discoveries for the development of antimetastasis medicines., (© 2023 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.)
- Published
- 2024
- Full Text
- View/download PDF
24. Magnetically controlled cyclic microscale deformation of in vitro cancer invasion models.
- Author
-
Asgeirsson DO, Mehta A, Scheeder A, Li F, Wang X, Christiansen MG, Hesse N, Ward R, De Micheli AJ, Ildiz ES, Menghini S, Aceto N, and Schuerle S
- Subjects
- Humans, Neoplasm Invasiveness, Cell Line, Tumor, Extracellular Matrix, Tumor Microenvironment, Models, Biological, Spheroids, Cellular
- Abstract
Mechanical cues play an important role in the metastatic cascade of cancer. Three-dimensional (3D) tissue matrices with tunable stiffness have been extensively used as model systems of the tumor microenvironment for physiologically relevant studies. Tumor-associated cells actively deform these matrices, providing mechanical cues to other cancer cells residing in the tissue. Mimicking such dynamic deformation in the surrounding tumor matrix may help clarify the effect of local strain on cancer cell invasion. Remotely controlled microscale magnetic actuation of such 3D in vitro systems is a promising approach, offering a non-invasive means for in situ interrogation. Here, we investigate the influence of cyclic deformation on tumor spheroids embedded in matrices, continuously exerted for days by cell-sized anisotropic magnetic probes, referred to as μRods. Particle velocimetry analysis revealed the spatial extent of matrix deformation produced in response to a magnetic field, which was found to be on the order of 200 μm, resembling strain fields reported to originate from contracting cells. Intracellular calcium influx was observed in response to cyclic actuation, as well as an influence on cancer cell invasion from 3D spheroids, as compared to unactuated controls. Furthermore, RNA sequencing revealed subtle upregulation of certain genes associated with migration and stress, such as induced through mechanical deformation, for spheroids exposed to actuation vs. controls. Localized actuation at one side of a tumor spheroid tended to result in anisotropic invasion toward the μRods causing the deformation. In summary, our approach offers a strategy to test and control the influence of non-invasive micromechanical cues on cancer cell invasion and metastasis.
- Published
- 2023
- Full Text
- View/download PDF
25. Mutant SF3B1 promotes malignancy in PDAC.
- Author
-
Simmler P, Ioannidi EI, Mengis T, Marquart KF, Asawa S, Van-Lehmann K, Kahles A, Thomas T, Schwerdel C, Aceto N, Rätsch G, Stoffel M, and Schwank G
- Subjects
- Animals, Humans, Mice, Cell Line, Tumor, Mutation, Pancreatic Ducts metabolism, Phosphoproteins metabolism, RNA Splicing Factors metabolism, Transcription Factors metabolism, Transforming Growth Factor beta1 metabolism, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal pathology, Pancreatic Neoplasms pathology
- Abstract
The splicing factor SF3B1 is recurrently mutated in various tumors, including pancreatic ductal adenocarcinoma (PDAC). The impact of the hotspot mutation SF3B1
K700E on the PDAC pathogenesis, however, remains elusive. Here, we demonstrate that Sf3b1K700E alone is insufficient to induce malignant transformation of the murine pancreas, but that it increases aggressiveness of PDAC if it co-occurs with mutated KRAS and p53. We further show that Sf3b1K700E already plays a role during early stages of pancreatic tumor progression and reduces the expression of TGF-β1-responsive epithelial-mesenchymal transition (EMT) genes. Moreover, we found that SF3B1K700E confers resistance to TGF-β1-induced cell death in pancreatic organoids and cell lines, partly mediated through aberrant splicing of Map3k7 . Overall, our findings demonstrate that SF3B1K700E acts as an oncogenic driver in PDAC, and suggest that it promotes the progression of early stage tumors by impeding the cellular response to tumor suppressive effects of TGF-β., Competing Interests: PS, EI, TM, KM, SA, KV, AK, TT, CS, NA, GR, MS, GS No competing interests declared, (© 2023, Simmler et al.)- Published
- 2023
- Full Text
- View/download PDF
26. Travelling under pressure - hypoxia and shear stress in the metastatic journey.
- Author
-
Ildiz ES, Gvozdenovic A, Kovacs WJ, and Aceto N
- Subjects
- Humans, Stress, Mechanical, Neoplasm Metastasis, Neoplastic Cells, Circulating pathology
- Abstract
Cancer cell invasion, intravasation and survival in the bloodstream are early steps of the metastatic process, pivotal to enabling the spread of cancer to distant tissues. Circulating tumor cells (CTCs) represent a highly selected subpopulation of cancer cells that tamed these critical steps, and a better understanding of their biology and driving molecular principles may facilitate the development of novel tools to prevent metastasis. Here, we describe key research advances in this field, aiming at describing early metastasis-related processes such as collective invasion, shedding, and survival of CTCs in the bloodstream, paying particular attention to microenvironmental factors like hypoxia and mechanical stress, considered as important influencers of the metastatic journey., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
27. Metastasis Unleashed: Hyposialylation Empowers Chemo-Evasive Circulating Tumor Cell Clusters in Breast Cancer.
- Author
-
Gvozdenovic A and Aceto N
- Subjects
- Humans, Cell Line, Tumor, Paclitaxel pharmacology, Paclitaxel therapeutic use, Neoplasm Metastasis, Neoplastic Cells, Circulating pathology, Triple Negative Breast Neoplasms drug therapy, Triple Negative Breast Neoplasms pathology
- Abstract
Therapy resistance is frequently observed in cancer patients with distant metastases and effective management of metastatic disease remains challenging. Unraveling the cellular mechanisms and molecular targets fueling metastatic spread is crucial for advancing cancer therapies. In a recent issue of Cancer Discovery, Dashzeveg and colleagues revealed that loss of terminal sialylation in glycoproteins within circulating tumor cell clusters is a dynamic process that contributes to cellular dormancy, facilitates evasion of chemotherapy, and enhances metastatic seeding. Furthermore, the study identifies the glycoprotein podocalyxin (PODXL) as a potential target for counteracting the metastasis of quiescent tumor cells associated with paclitaxel treatment in triple-negative breast cancer., (©2023 American Association for Cancer Research.)
- Published
- 2023
- Full Text
- View/download PDF
28. A new time dimension in the fight against metastasis.
- Author
-
Diamantopoulou Z, Gvozdenovic A, and Aceto N
- Subjects
- Humans, Chronotherapy methods, Biomarkers, Circadian Rhythm, Neoplastic Cells, Circulating
- Abstract
Despite advances in uncovering vulnerabilities, identifying biomarkers, and developing more efficient treatments, cancer remains a threat because of its ability to progress while acquiring resistance to therapy. The circadian rhythm governs most of the cellular functions implicated in cancer progression, and its exploitation therefore opens new promising directions in the fight against metastasis. In this review we summarize the role of the circadian rhythm in tumor development and progression, with emphasis on the circadian rhythm-regulated elements that control the generation of circulating tumor cells (CTCs) and metastasis. We then present data on chronotherapy and discuss how circadian rhythm investigations may open new paths to more effective anticancer treatments., Competing Interests: Declaration of interests N.A. is cofounder and member of the board of PAGE Therapeutics AG, Switzerland, listed as inventor in patent applications related to CTCs, a paid consultant for companies with an interest in liquid biopsies, and a Novartis shareholder. The other authors declare no conflicts of interest., (Copyright © 2023 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
29. Resistance to mesenchymal reprogramming sustains clonal propagation in metastatic breast cancer.
- Author
-
Saini M, Schmidleitner L, Moreno HD, Donato E, Falcone M, Bartsch JM, Klein C, Vogel V, Würth R, Pfarr N, Espinet E, Lehmann M, Königshoff M, Reitberger M, Haas S, Graf E, Schwarzmayr T, Strom TM, Spaich S, Sütterlin M, Schneeweiss A, Weichert W, Schotta G, Reichert M, Aceto N, Sprick MR, Trumpp A, and Scheel CH
- Subjects
- Humans, Female, Epithelial Cell Adhesion Molecule, Cell Line, Tumor, Breast metabolism, Clone Cells metabolism, Epithelial-Mesenchymal Transition, Breast Neoplasms pathology
- Abstract
The acquisition of mesenchymal traits is considered a hallmark of breast cancer progression. However, the functional relevance of epithelial-to-mesenchymal transition (EMT) remains controversial and context dependent. Here, we isolate epithelial and mesenchymal populations from human breast cancer metastatic biopsies and assess their functional potential in vivo. Strikingly, progressively decreasing epithelial cell adhesion molecule (EPCAM) levels correlate with declining disease propagation. Mechanistically, we find that persistent EPCAM expression marks epithelial clones that resist EMT induction and propagate competitively. In contrast, loss of EPCAM defines clones arrested in a mesenchymal state, with concomitant suppression of tumorigenicity and metastatic potential. This dichotomy results from distinct clonal trajectories impacting global epigenetic programs that are determined by the interplay between human ZEB1 and its target GRHL2. Collectively, our results indicate that susceptibility to irreversible EMT restrains clonal propagation, whereas resistance to mesenchymal reprogramming sustains disease spread in multiple models of human metastatic breast cancer, including patient-derived cells in vivo., Competing Interests: Declaration of interests The authors declare no competing interests., (Copyright © 2023 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
30. Circulating tumour cells in gastrointestinal cancers: food for thought?
- Author
-
Asawa S, Nüesch M, Gvozdenovic A, and Aceto N
- Subjects
- Humans, Prospective Studies, Lung, Prognosis, Neoplasm Metastasis pathology, Biomarkers, Tumor, Neoplastic Cells, Circulating pathology, Gastrointestinal Neoplasms pathology
- Abstract
Gastrointestinal (GI) cancers account for 35% of cancer-related deaths, predominantly due to their ability to spread and generate drug-tolerant metastases. Arising from different locations in the GI system, the majority of metastatic GI malignancies colonise the liver and the lungs. In this context, circulating tumour cells (CTCs) are playing a critical role in the formation of new metastases, and their presence in the blood of patients has been correlated with a poor outcome. In addition to their prognostic utility, prospective targeting of CTCs may represent a novel, yet ambitious strategy in the fight against metastasis. A better understanding of CTC biology, mechanistic underpinnings and weaknesses may facilitate the development of previously underappreciated anti-metastasis approaches. Here, along with related clinical studies, we outline a selection of the literature describing biological features of CTCs with an impact on their metastasis forming ability in different GI cancers., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
31. Biology, vulnerabilities and clinical applications of circulating tumour cells.
- Author
-
Ring A, Nguyen-Sträuli BD, Wicki A, and Aceto N
- Subjects
- Humans, Liquid Biopsy, Biology, Neoplastic Cells, Circulating pathology
- Abstract
In recent years, exceptional technological advances have enabled the identification and interrogation of rare circulating tumour cells (CTCs) from blood samples of patients, leading to new fields of research and fostering the promise for paradigm-changing, liquid biopsy-based clinical applications. Analysis of CTCs has revealed distinct biological phenotypes, including the presence of CTC clusters and the interaction between CTCs and immune or stromal cells, impacting metastasis formation and providing new insights into cancer vulnerabilities. Here we review the progress made in understanding biological features of CTCs and provide insight into exploiting these developments to design future clinical tools for improving the diagnosis and treatment of cancer., (© 2022. Springer Nature Limited.)
- Published
- 2023
- Full Text
- View/download PDF
32. MyCTC chip: microfluidic-based drug screen with patient-derived tumour cells from liquid biopsies.
- Author
-
Schwab FD, Scheidmann MC, Ozimski LL, Kling A, Armbrecht L, Ryser T, Krol I, Strittmatter K, Nguyen-Sträuli BD, Jacob F, Fedier A, Heinzelmann-Schwarz V, Wicki A, Dittrich PS, and Aceto N
- Abstract
Cancer patients with advanced disease are characterized by intrinsic challenges in predicting drug response patterns, often leading to ineffective treatment. Current clinical practice for treatment decision-making is commonly based on primary or secondary tumour biopsies, yet when disease progression accelerates, tissue biopsies are not performed on a regular basis. It is in this context that liquid biopsies may offer a unique window to uncover key vulnerabilities, providing valuable information about previously underappreciated treatment opportunities. Here, we present MyCTC chip, a novel microfluidic device enabling the isolation, culture and drug susceptibility testing of cancer cells derived from liquid biopsies. Cancer cell capture is achieved through a label-free, antigen-agnostic enrichment method, and it is followed by cultivation in dedicated conditions, allowing on-chip expansion of captured cells. Upon growth, cancer cells are then transferred to drug screen chambers located within the same device, where multiple compounds can be tested simultaneously. We demonstrate MyCTC chip performance by means of spike-in experiments with patient-derived breast circulating tumour cells, enabling >95% capture rates, as well as prospective processing of blood from breast cancer patients and ascites fluid from patients with ovarian, tubal and endometrial cancer, where sensitivity to specific chemotherapeutic agents was identified. Together, we provide evidence that MyCTC chip may be used to identify personalized drug response patterns in patients with advanced metastatic disease and with limited treatment opportunities., Competing Interests: Conflict of interestN.A. is a co-founder and member of the Board of PAGE Therapeutics AG, consultant for companies with an interest in liquid biopsy, and Novartis shareholder. M.C.S. is an employee at Novartis Pharma AG and a Novartis shareholder. All other authors declare no competing interests., (© The Author(s) 2022.)
- Published
- 2022
- Full Text
- View/download PDF
33. EMP1-positive cells found guilty of metastatic relapse in colorectal cancer.
- Author
-
Gvozdenovic A and Aceto N
- Subjects
- Humans, Receptors, Cell Surface metabolism, Recurrence, Neoplasm Proteins metabolism, Colorectal Neoplasms pathology
- Abstract
Metastatic recurrence develops in 30%-40% of colorectal cancer (CRC) patients in the years that follow surgical removal of the primary tumor. In a recent issue of Nature, Cañellas-Socias et al. identify a distinct population of CRC cells, marked with epithelial membrane protein 1 (EMP1), accountable for metastatic relapse., Competing Interests: Declaration of interests N.A. is a co-founder and member of the board of PAGE Therapeutics AG, Switzerland; listed as an inventor in patent applications related to CTCs; is a paid consultant for companies with an interest in liquid biopsy; and is a Novartis shareholder., (Copyright © 2022 Elsevier Inc. All rights reserved.)
- Published
- 2022
- Full Text
- View/download PDF
34. The gate to metastasis: key players in cancer cell intravasation.
- Author
-
Sznurkowska MK and Aceto N
- Subjects
- Humans, Neoplasm Metastasis, Tumor Microenvironment, Neoplasms genetics, Neoplasms pathology
- Abstract
Metastasis is a leading cause of cancer-related death and consists of a sequence of events including tumor expansion, intravasation of cancer cells into the circulation, survival in the bloodstream, extravasation at distant sites, and subsequent organ colonization. Particularly, intravasation is a process whereby cancer cells transverse the endothelium and leave the primary tumor site, pioneering the metastatic cascade. The identification of those mechanisms that trigger the entry of cancer cells into the bloodstream may reveal fundamentally novel ways to block metastasis at its start. Multiple factors have been implicated in cancer progression, yet, signals that unequivocally provoke the detachment of cancer cells from the primary tumor are still under investigation. Here, we discuss the role of intrinsic properties of cancer cells, tumor microenvironment, and mechanical cues in the intravasation process, outlining studies that suggest the involvement of various factors and highlighting current understanding and open questions in the field., (© 2021 The Authors. The FEBS Journal published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies.)
- Published
- 2022
- Full Text
- View/download PDF
35. NfκB signaling dynamics and their target genes differ between mouse blood cell types and induce distinct cell behavior.
- Author
-
Kull T, Wehling A, Etzrodt M, Auler M, Dettinger P, Aceto N, and Schroeder T
- Subjects
- Animals, Blood Cells metabolism, Cell Differentiation genetics, Mice, Signal Transduction, Hematopoietic Stem Cells metabolism, NF-kappa B metabolism
- Abstract
Cells can use signaling pathway activity over time (ie, dynamics) to control cell fates. However, little is known about the potential existence and function of signaling dynamics in primary hematopoietic stem and progenitor cells (HSPCs). Here, we use time-lapse imaging and tracking of single murine HSPCs from green fluorescent protein-p65/H2BmCherry reporter mice to quantify their nuclear factor κB (NfκB) activity dynamics in response to tumor necrosis factor α and interleukin 1β. We find response dynamics to be heterogeneous between individual cells, with cell type-specific dynamics distributions. Transcriptome sequencing of single cells physically isolated after live dynamics quantification shows activation of different target gene programs in cells with different dynamics. Finally, artificial induction of oscillatory NfκB activity causes changes in granulocyte/monocyte progenitor behavior. Thus, HSPC behavior can be influenced by signaling dynamics, which are tightly regulated during hematopoietic differentiation and enable cell type-specific responses to the same signaling inputs., (© 2022 by The American Society of Hematology.)
- Published
- 2022
- Full Text
- View/download PDF
36. ICAM-1 on Breast Cancer Cells Suppresses Lung Metastasis but Is Dispensable for Tumor Growth and Killing by Cytotoxic T Cells.
- Author
-
Regev O, Kizner M, Roncato F, Dadiani M, Saini M, Castro-Giner F, Yajuk O, Kozlovski S, Levi N, Addadi Y, Golani O, Ben-Dor S, Granot Z, Aceto N, and Alon R
- Subjects
- Animals, Cell Line, Tumor, Intercellular Adhesion Molecule-1 metabolism, Mice, Mice, Inbred C57BL, Ovalbumin, Tumor Microenvironment, Lung Neoplasms pathology, T-Lymphocytes, Cytotoxic
- Abstract
Breast tumors and their derived circulating cancer cells express the leukocyte β
2 integrin ligand Intercellular adhesion molecule 1 (ICAM-1). We found that elevated ICAM-1 expression in breast cancer cells results in a favorable outcome and prolonged survival of breast cancer patients. We therefore assessed the direct in vivo contribution of ICAM-1 expressed by breast cancer cells to breast tumorigenesis and lung metastasis in syngeneic immunocompetent mice hosts using spontaneous and experimental models of the lung metastasis of the C57BL/6-derived E0771 cell line, a luminal B breast cancer subtype. Notably, the presence of ICAM-1 on E0771 did not alter tumor growth or the leukocyte composition in the tumor microenvironment. Interestingly, the elimination of Tregs led to the rapid killing of primary tumor cells independently of tumor ICAM-1 expression. The in vivo elimination of a primary E0771 tumor expressing the ovalbumin (OVA) model neoantigen by the OVA-specific OVA-tcr-I mice (OT-I) transgenic cytotoxic T lymphocytes (CTLs) also took place normally in the absence of ICAM-1 expression by E0771 breast cancer target cells. The whole lung imaging of these cells by light sheet microscopy (LSM) revealed that both Wild type (WT)- and ICAM-1-deficient E0771 cells were equally disseminated from resected tumors and accumulated inside the lung vasculature at similar magnitudes. ICAM-1-deficient breast cancer cells developed, however, much larger metastatic lesions than their control counterparts. Strikingly, the vast majority of these cells gave rise to intravascular tumor colonies both in spontaneous and experimental metastasis models. In the latter model, ICAM-1 expressing E0771- but not their ICAM-1-deficient counterparts were highly susceptible to elimination by neutrophils adoptively transferred from E0771 tumor-bearing donor mice. Ex vivo , neutrophils derived from tumor-bearing mice also killed cultured E0771 cells via ICAM-1-dependent interactions. Collectively, our results are a first indication that ICAM-1 expressed by metastatic breast cancer cells that expand inside the lung vasculature is involved in innate rather than in adaptive cancer cell killing. This is also a first indication that the breast tumor expression of ICAM-1 is not required for CTL-mediated killing but can function as a suppressor of intravascular breast cancer metastasis to lungs., Competing Interests: NA is a paid consultant for companies with an interest in liquid biopsy. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Regev, Kizner, Roncato, Dadiani, Saini, Castro-Giner, Yajuk, Kozlovski, Levi, Addadi, Golani, Ben-Dor, Granot, Aceto and Alon.)- Published
- 2022
- Full Text
- View/download PDF
37. The metastatic spread of breast cancer accelerates during sleep.
- Author
-
Diamantopoulou Z, Castro-Giner F, Schwab FD, Foerster C, Saini M, Budinjas S, Strittmatter K, Krol I, Seifert B, Heinzelmann-Schwarz V, Kurzeder C, Rochlitz C, Vetter M, Weber WP, and Aceto N
- Subjects
- Animals, Cell Count, Cell Proliferation, Disease Models, Animal, Female, Glucocorticoids, Humans, Insulin, Melatonin, Mice, Neoplastic Cells, Circulating pathology, RNA-Seq, Single-Cell Analysis, Testosterone, Time Factors, Breast Neoplasms pathology, Neoplasm Metastasis pathology, Sleep
- Abstract
The metastatic spread of cancer is achieved by the haematogenous dissemination of circulating tumour cells (CTCs). Generally, however, the temporal dynamics that dictate the generation of metastasis-competent CTCs are largely uncharacterized, and it is often assumed that CTCs are constantly shed from growing tumours or are shed as a consequence of mechanical insults
1 . Here we observe a striking and unexpected pattern of CTC generation dynamics in both patients with breast cancer and mouse models, highlighting that most spontaneous CTC intravasation events occur during sleep. Further, we demonstrate that rest-phase CTCs are highly prone to metastasize, whereas CTCs generated during the active phase are devoid of metastatic ability. Mechanistically, single-cell RNA sequencing analysis of CTCs reveals a marked upregulation of mitotic genes exclusively during the rest phase in both patients and mouse models, enabling metastasis proficiency. Systemically, we find that key circadian rhythm hormones such as melatonin, testosterone and glucocorticoids dictate CTC generation dynamics, and as a consequence, that insulin directly promotes tumour cell proliferation in vivo, yet in a time-dependent manner. Thus, the spontaneous generation of CTCs with a high proclivity to metastasize does not occur continuously, but it is concentrated within the rest phase of the affected individual, providing a new rationale for time-controlled interrogation and treatment of metastasis-prone cancers., (© 2022. The Author(s), under exclusive licence to Springer Nature Limited.)- Published
- 2022
- Full Text
- View/download PDF
38. Clinical and Biological Aspects of Disseminated Tumor Cells and Dormancy in Breast Cancer.
- Author
-
Ring A, Spataro M, Wicki A, and Aceto N
- Abstract
Progress in detection and treatment have drastically improved survival for early breast cancer patients. However, distant recurrence causes high mortality and is typically considered incurable. Cancer dissemination occurs via circulating tumor cells (CTCs) and up to 75% of breast cancer patients could harbor micrometastatses at time of diagnosis, while metastatic recurrence often occurs years to decades after treatment. During clinical latency, disseminated tumor cells (DTCs) can enter a state of cell cycle arrest or dormancy at distant sites, and are likely shielded from immune detection and treatment. While this is a challenge, it can also be seen as an outstanding opportunity to target dormant DTCs on time, before their transformation into lethal macrometastatic lesions. Here, we review and discuss progress made in our understanding of DTC and dormancy biology in breast cancer. Strides in our mechanistic insights of these features has led to the identification of possible targeting strategies, yet, their integration into clinical trial design is still uncertain. Incorporating minimally invasive liquid biopsies and rationally designed adjuvant therapies, targeting both proliferating and dormant tumor cells, may help to address current challenges and improve precision cancer care., Competing Interests: NA is co-founder and member of the board of PAGE Therapeutics AG, Switzerland, listed as inventor in patent applications related to the metastatic process and a paid consultant for companies with an interest in liquid biopsy. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Ring, Spataro, Wicki and Aceto.)
- Published
- 2022
- Full Text
- View/download PDF
39. Protein Tyrosine Phosphatase SHP2 Controls Interleukin-8 Expression in Breast Cancer Cells.
- Author
-
Amante RJ, Auf der Maur P, Richina V, Sethi A, Iesmantavicius V, Bonenfant D, Aceto N, and Bentires-Alj M
- Subjects
- Cell Line, Tumor, Female, Humans, Proteome, Transcription Factors, Tyrosine, Breast Neoplasms pathology, Interleukin-8
- Abstract
Treatment of metastasis remains a clinical challenge and the majority of breast cancer-related deaths are the result of drug-resistant metastases. The protein tyrosine phosphatase SHP2 encoded by the proto-oncogene PTPN11 promotes breast cancer progression. Inhibition of SHP2 has been shown to decrease metastases formation in various breast cancer models, but specific downstream effectors of SHP2 remain poorly characterized. Certain cytokines in the metastatic cascade facilitate local invasion and promote metastatic colonization. In this study, we investigated cytokines affected by SHP2 that could be relevant for its pro-tumorigenic properties. We used a cytokine array to investigate differentially released cytokines in the supernatant of SHP2 inhibitor-treated breast cancer cells. Expression of CXCL8 transcripts and protein abundance were assessed in human breast cancer cell lines in which we blocked SHP2 using shRNA constructs or an allosteric inhibitor. The impact of SHP2 inhibition on the phospho-tyrosine-proteome and signaling was determined using mass spectrometry. From previously published RNAseq data (Aceto et al. in Nat. Med. 18:529-37, 2012), we computed transcription factor activities using an integrated system for motif activity response analysis (ISMARA) (Balwierz et al. in Genome Res. 24:869-84, 2014). Finally, using siRNA against ETS1, we investigated whether ETS1 directly influences CXCL8 expression levels. We found that IL-8 is one of the most downregulated cytokines in cell supernatants upon SHP2 blockade, with a twofold decrease in CXCL8 transcripts and a fourfold decrease in IL-8 protein. These effects were also observed in preclinical tumor models. Analysis of the phospho-tyrosine-proteome revealed that several effectors of the mitogen-activated protein kinase (MAPK) pathway are downregulated upon SHP2 inhibition in vitro. MEK1/2 inhibition consistently reduced IL-8 levels in breast cancer cell supernatants. Computational analysis of RNAseq data from SHP2-depleted tumors revealed reduced activity of the transcription factor ETS1, a direct target of ERK and a transcription factor reported to regulate IL-8 expression. Our work reveals that SHP2 mediates breast cancer progression by enhancing the production and secretion of the pro-metastatic cytokine IL-8. We also provide mechanistic insights into the effects of SHP2 inhibition and its downstream repercussions. Overall, these results support a rationale for targeting SHP2 in breast cancer., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
40. Cooperative interaction between ERα and the EMT-inducer ZEB1 reprograms breast cancer cells for bone metastasis.
- Author
-
Mohammadi Ghahhari N, Sznurkowska MK, Hulo N, Bernasconi L, Aceto N, and Picard D
- Subjects
- Cell Line, Tumor, Epithelial-Mesenchymal Transition physiology, Estrogen Receptor alpha genetics, Estrogen Receptor alpha metabolism, Female, Gene Expression Regulation, Neoplastic, Humans, Neoplasm Metastasis, Transcription Factors metabolism, Zinc Finger E-box-Binding Homeobox 1 genetics, Zinc Finger E-box-Binding Homeobox 1 metabolism, Bone Neoplasms genetics, Breast Neoplasms pathology
- Abstract
The epithelial to mesenchymal transition (EMT) has been proposed to contribute to the metastatic spread of breast cancer cells. EMT-promoting transcription factors determine a continuum of different EMT states. In contrast, estrogen receptor α (ERα) helps to maintain the epithelial phenotype of breast cancer cells and its expression is crucial for effective endocrine therapies. Determining whether and how EMT-associated transcription factors such as ZEB1 modulate ERα signaling during early stages of EMT could promote the discovery of therapeutic approaches to suppress metastasis. Here we show that, shortly after induction of EMT and while cells are still epithelial, ZEB1 modulates ERα-mediated transcription induced by estrogen or cAMP signaling in breast cancer cells. Based on these findings and our ex vivo and xenograft results, we suggest that the functional interaction between ZEB1 and ERα may alter the tissue tropism of metastatic breast cancer cells towards bone., (© 2022. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
41. An In Vivo CRISPR Screen Identifies Stepwise Genetic Dependencies of Metastatic Progression.
- Author
-
Scheidmann MC, Castro-Giner F, Strittmatter K, Krol I, Paasinen-Sohns A, Scherrer R, Donato C, Gkountela S, Szczerba BM, Diamantopoulou Z, Muenst S, Vlajnic T, Kunz L, Vetter M, Rochlitz C, Taylor V, Giachino C, Schroeder T, Platt RJ, and Aceto N
- Subjects
- Animals, Biomarkers, Tumor metabolism, Breast Neoplasms blood, Breast Neoplasms pathology, CRISPR-Cas Systems, Cell Cycle Proteins genetics, Cell Cycle Proteins metabolism, Cell Line, Tumor, Female, Gene Expression Regulation, Neoplastic, Humans, Mice, Inbred NOD, Mice, Knockout, Mice, SCID, Neoplasm Metastasis, Neoplastic Cells, Circulating pathology, Protein Serine-Threonine Kinases genetics, Protein Serine-Threonine Kinases metabolism, Proto-Oncogene Proteins genetics, Proto-Oncogene Proteins metabolism, RNA, Guide, CRISPR-Cas Systems genetics, RNA, Guide, CRISPR-Cas Systems metabolism, RNA-Seq methods, Survival Analysis, Xenograft Model Antitumor Assays methods, Polo-Like Kinase 1, Mice, Biomarkers, Tumor genetics, Breast Neoplasms genetics, Clustered Regularly Interspaced Short Palindromic Repeats genetics, Neoplastic Cells, Circulating metabolism
- Abstract
Blood-borne metastasis of breast cancer involves a series of tightly regulated sequential steps, including the growth of a primary tumor lesion, intravasation of circulating tumor cells (CTC), and adaptation in various distant metastatic sites. The genes orchestrating each of these steps are poorly understood in physiologically relevant contexts, owing to the rarity of experimental models that faithfully recapitulate the biology, growth kinetics, and tropism of human breast cancer. Here, we conducted an in vivo loss-of-function CRISPR screen in newly derived CTC xenografts, unique in their ability to spontaneously mirror the human disease, and identified specific genetic dependencies for each step of the metastatic process. Validation experiments revealed sensitivities to inhibitors that are already available, such as PLK1 inhibitors, to prevent CTC intravasation. Together, these findings present a new tool to reclassify driver genes involved in the spread of human cancer, providing insights into the biology of metastasis and paving the way to test targeted treatment approaches., Significance: A loss-of-function CRISPR screen in human CTC-derived xenografts identifies genes critical for individual steps of the metastatic cascade, suggesting novel drivers and treatment opportunities for metastatic breast cancers., (©2021 The Authors; Published by the American Association for Cancer Research.)
- Published
- 2022
- Full Text
- View/download PDF
42. Cooperation between melanoma cell states promotes metastasis through heterotypic cluster formation.
- Author
-
Campbell NR, Rao A, Hunter MV, Sznurkowska MK, Briker L, Zhang M, Baron M, Heilmann S, Deforet M, Kenny C, Ferretti LP, Huang TH, Perlee S, Garg M, Nsengimana J, Saini M, Montal E, Tagore M, Newton-Bishop J, Middleton MR, Corrie P, Adams DJ, Rabbie R, Aceto N, Levesque MP, Cornell RA, Yanai I, Xavier JB, and White RM
- Subjects
- Animals, Gene Expression Regulation, Neoplastic physiology, Melanoma pathology, Neural Crest pathology, Zebrafish, Cluster Analysis, Melanoma metabolism, Neoplasm Metastasis pathology, Neoplastic Cells, Circulating pathology
- Abstract
Melanomas can have multiple coexisting cell states, including proliferative (PRO) versus invasive (INV) subpopulations that represent a "go or grow" trade-off; however, how these populations interact is poorly understood. Using a combination of zebrafish modeling and analysis of patient samples, we show that INV and PRO cells form spatially structured heterotypic clusters and cooperate in the seeding of metastasis, maintaining cell state heterogeneity. INV cells adhere tightly to each other and form clusters with a rim of PRO cells. Intravital imaging demonstrated cooperation in which INV cells facilitate dissemination of less metastatic PRO cells. We identified the TFAP2 neural crest transcription factor as a master regulator of clustering and PRO/INV states. Isolation of clusters from patients with metastatic melanoma revealed a subset with heterotypic PRO-INV clusters. Our data suggest a framework for the co-existence of these two divergent cell populations, in which heterotypic clusters promote metastasis via cell-cell cooperation., Competing Interests: Declaration of interests M.R.M. receives research funding from GRAIL. D.J.A. is a paid consultant for Microbiotica and receives researching funding from Astra Zeneca and OpenTargets. M.P.L. receives research funding from Roche and Novartis. N.A. is a paid consultant for companies with an interest in liquid biopsy. R.M.W. is a paid consultant to N-of-One Therapeutics, a subsidiary of Qiagen. R.M.W. is on the Scientific Advisory Board of Consano but receives no income for this. R.M.W. receives royalty payments for the use of the casper line from Carolina Biologicals., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
43. CD44v6 Defines a New Population of Circulating Tumor Cells Not Expressing EpCAM.
- Author
-
Belthier G, Homayed Z, Grillet F, Duperray C, Vendrell J, Krol I, Bravo S, Boyer JC, Villeronce O, Vitre-Boubaker J, Heaug-Wane D, Macari-Fine F, Smith J, Merlot M, Lossaint G, Mazard T, Portales F, Solassol J, Ychou M, Aceto N, Mamessier E, Bertucci F, Pascussi JM, Samalin E, Hollande F, and Pannequin J
- Abstract
Circulating tumor cells (CTCs) are promising diagnostic and prognostic tools for clinical use. In several cancers, including colorectal and breast, the CTC load has been associated with a therapeutic response as well as progression-free and overall survival. However, counting and isolating CTCs remains sub-optimal because they are currently largely identified by epithelial markers such as EpCAM. New, complementary CTC surface markers are therefore urgently needed. We previously demonstrated that a splice variant of CD44, CD44 variable alternative exon 6 (CD44v6), is highly and specifically expressed by CTC cell lines derived from blood samples in colorectal cancer (CRC) patients. Two different approaches-immune detection coupled with magnetic beads and fluorescence-activated cell sorting-were optimized to purify CTCs from patient blood samples based on high expressions of CD44v6. We revealed the potential of the CD44v6 as a complementary marker to EpCAM to detect and purify CTCs in colorectal cancer blood samples. Furthermore, this marker is not restricted to colorectal cancer since CD44v6 is also expressed on CTCs from breast cancer patients. Overall, these results strongly suggest that CD44v6 could be useful to enumerate and purify CTCs from cancers of different origins, paving the way to more efficacious combined markers that encompass CTC heterogeneity.
- Published
- 2021
- Full Text
- View/download PDF
44. A fatal affair: Circulating tumor cell relationships that shape metastasis.
- Author
-
Ozimski LL, Gremmelspacher D, and Aceto N
- Abstract
Circulating tumor cells are metastatic precursors in several cancer types. Their biology and clinical utility are subject to numerous investigations, yet one aspect that is often neglected is their entanglement with the tumor microenvironment, namely the cross talk with stromal and immune cells and their relationships with other tumor-derived components such as circulating tumor DNA and extracellular vesicles in circulation. We will focus our short review specifically on these aspects, i.e., providing some examples of the liaison that circulating tumor cells have with stromal or immune cells and illustrating their relationship with other circulating tumor derivatives such as circulating tumor DNA and extracellular vesicles., Competing Interests: N.A. is a paid consultant for companies with an interest in liquid biopsy. All other authors declare no conflict of interest., (© 2021 The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
45. Evaluation of endocrine resistance using ESR1 genotyping of circulating tumor cells and plasma DNA.
- Author
-
Sundaresan TK, Dubash TD, Zheng Z, Bardia A, Wittner BS, Aceto N, Silva EJ, Fox DB, Liebers M, Kapur R, Iafrate J, Toner M, Maheswaran S, and Haber DA
- Subjects
- Estrogen Receptor alpha genetics, Female, Genotype, Humans, Mutation, Neoplasm Recurrence, Local, Prospective Studies, Breast Neoplasms, Circulating Tumor DNA, Neoplastic Cells, Circulating
- Abstract
Purpose: Therapeutic efficacy of hormonal therapies to target estrogen receptor (ER)-positive breast cancer is limited by the acquisition of ligand-independent ESR1 mutations, which confer treatment resistance to aromatase inhibitors (AIs). Monitoring for the emergence of such mutations may enable individualized therapy. We thus assessed CTC- and ctDNA-based detection of ESR1 mutations with the aim of evaluating non-invasive approaches for the determination of endocrine resistance., Patients and Methods: In a prospective cohort of 55 women with hormone receptor-positive metastatic breast cancer, we isolated circulating tumor cells (CTCs) and developed a high-sensitivity method for the detection of ESR1 mutations in these CTCs. In patients with sufficient plasma for the simultaneous extraction of circulating tumor DNA (ctDNA), we performed a parallel analysis of ESR1 mutations using multiplex droplet digital PCR (ddPCR) and examined the agreement between these two platforms. Finally, we isolated single CTCs from a subset of these patients and reviewed RNA expression to explore alternate methods of evaluating endocrine responsiveness., Results: High-sensitivity ESR1 sequencing from CTCs revealed mono- and oligoclonal mutations in 22% of patients. These were concordant with plasma DNA sequencing in 95% of cases. Emergence of ESR1 mutations was correlated both with time to metastatic relapse and duration of AI therapy following such recurrence. The Presence of an ESR1 mutation, compared to ESR1 wild type, was associated with markedly shorter Progression-Free Survival on AI-based therapies (p = 0.0006), but unaltered to other non-AI-based therapies (p = 0.73). Compared with ESR1 mutant cases, AI-resistant CTCs with wild-type ESR1 showed an elevated ER-coactivator RNA signature, consistent with their predicted response to second-line hormonal therapies., Conclusion: Blood-based serial monitoring may guide the selection of precision therapeutics for women with AI-resistant ER-positive breast cancer.
- Published
- 2021
- Full Text
- View/download PDF
46. Detection of clustered circulating tumour cells in early breast cancer.
- Author
-
Krol I, Schwab FD, Carbone R, Ritter M, Picocci S, De Marni ML, Stepien G, Franchi GM, Zanardi A, Rissoglio MD, Covelli A, Guidi G, Scarinci D, Castro-Giner F, Mazzarella L, Doglioni C, Borghi F, Milani P, Kurzeder C, Weber WP, and Aceto N
- Subjects
- Breast Neoplasms surgery, Case-Control Studies, Cell Line, Tumor, Female, Humans, Nanostructures, Neoplasm Metastasis, Neoplasm Staging, Breast Neoplasms pathology, Neoplastic Cells, Circulating pathology, Titanium chemistry
- Abstract
Circulating tumour cell (CTC) clusters have been proposed to be major players in the metastatic spread of breast cancer, particularly during advanced disease stages. Yet, it is unclear whether or not they manifest in early breast cancer, as their occurrence in patients with metastasis-free primary disease has not been thoroughly evaluated. In this study, exploiting nanostructured titanium oxide-coated slides for shear-free CTC identification, we detect clustered CTCs in the curative setting of multiple patients with early breast cancer prior to surgical treatment, highlighting their presence already at early disease stages. These results spotlight an important aspect of metastasis biology and the possibility to intervene with anti-cluster therapeutics already during the early manifestation of breast cancer.
- Published
- 2021
- Full Text
- View/download PDF
47. Mass spectrometry analysis of circulating breast cancer cells from a Xenograft mouse model.
- Author
-
Donato C, Buczak K, Schmidt A, and Aceto N
- Subjects
- Animals, Female, Heterografts, Humans, Mice, Neoplasm Transplantation, Proteome chemistry, Proteomics, Breast Neoplasms chemistry, Mass Spectrometry methods, Neoplastic Cells, Circulating chemistry, Proteome analysis
- Abstract
Circulating tumor cells (CTCs) are precursors of metastasis in various cancer types. Many aspects regarding CTC biology remain poorly understood. Here, we describe mass spectrometric analysis of CTCs from a breast cancer xenograft mouse model, including procedures comprising CTC enrichment, separation of different CTC subpopulations, and their quantitative proteomic assessment. This protocol aims to facilitate the identification of protein content dynamics in human CTCs that are physiologically shed from tumor-bearing xenografts, providing a framework for investigating metastasis biology. For complete details on the use and execution of this protocol, please refer to Donato et al. (2020)., Competing Interests: N.A. and C.D. are listed as inventors in patent application EP 19188215.8, ‘‘Angiogenesis promoting agents for prevention of metastatic cancer.’’ N.A. is a paid consultant for companies with an interest in liquid biopsy., (© 2021 The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
48. High blood flow shear stress values are associated with circulating tumor cells cluster disaggregation in a multi-channel microfluidic device.
- Author
-
Marrella A, Fedi A, Varani G, Vaccari I, Fato M, Firpo G, Guida P, Aceto N, and Scaglione S
- Subjects
- Biomechanical Phenomena, Cell Line, Tumor, Cell Survival, Humans, Models, Biological, Neoplasm Metastasis, Single-Cell Analysis, Hemodynamics, Lab-On-A-Chip Devices, Neoplastic Cells, Circulating pathology, Shear Strength, Stress, Mechanical
- Abstract
Metastasis represents a dynamic succession of events involving tumor cells which disseminate through the organism via the bloodstream. Circulating tumor cells (CTCs) can flow the bloodstream as single cells or as multicellular aggregates (clusters), which present a different potential to metastasize. The effects of the bloodstream-related physical constraints, such as hemodynamic wall shear stress (WSS), on CTC clusters are still unclear. Therefore, we developed, upon theoretical and CFD modeling, a new multichannel microfluidic device able to simultaneously reproduce different WSS characterizing the human circulatory system, where to analyze the correlation between SS and CTC clusters behavior. Three physiological WSS levels (i.e. 2, 5, 20 dyn/cm2) were generated, reproducing values typical of capillaries, veins and arteries. As first validation, triple-negative breast cancer cells (MDA-MB-231) were injected as single CTCs showing that higher values of WSS are correlated with a decreased viability. Next, the SS-mediated disaggregation of CTC clusters was computationally investigated in a vessels-mimicking domain. Finally, CTC clusters were injected within the three different circuits and subjected to the three different WSS, revealing that increasing WSS levels are associated with a raising clusters disaggregation after 6 hours of circulation. These results suggest that our device may represent a valid in vitro tool to carry out systematic studies on the biological significance of blood flow mechanical forces and eventually to promote new strategies for anticancer therapy., Competing Interests: The authors have declared that no competing interests exist.
- Published
- 2021
- Full Text
- View/download PDF
49. Multi-color clonal tracking reveals intra-stage proliferative heterogeneity during mammary tumor progression.
- Author
-
Tiede S, Kalathur RKR, Lüönd F, von Allmen L, Szczerba BM, Hess M, Vlajnic T, Müller B, Canales Murillo J, Aceto N, and Christofori G
- Subjects
- Animals, Breast Neoplasms genetics, Cell Line, Tumor, Cell Proliferation, Clonal Evolution, Disease Progression, Female, Gene Regulatory Networks, Humans, Laser Capture Microdissection, Mammary Neoplasms, Experimental genetics, Mammary Neoplasms, Experimental virology, Mice, Neoplasm Metastasis, Neoplasm Staging, Sequence Analysis, RNA, Breast Neoplasms pathology, Cell Tracking methods, Gene Expression Profiling methods, Mammary Neoplasms, Experimental pathology, Mammary Tumor Virus, Mouse pathogenicity, Receptor, ErbB-2 genetics
- Abstract
Despite major progress in breast cancer research, the functional contribution of distinct cancer cell clones to malignant tumor progression and metastasis remains largely elusive. We have assessed clonal heterogeneity within individual primary tumors and metastases and also during the distinct stages of malignant tumor progression using clonal tracking of cancer cells in the MMTV-PyMT mouse model of metastatic breast cancer. Comparative gene expression analysis of clonal subpopulations reveals a substantial level of heterogeneity across and also within the various stages of breast carcinogenesis. The intra-stage heterogeneity is primarily manifested by differences in cell proliferation, also found within invasive carcinomas of luminal A-, luminal B-, and HER2-enriched human breast cancer. Surprisingly, in the mouse model of clonal tracing of cancer cells, chemotherapy mainly targets the slow-proliferative clonal populations and fails to efficiently repress the fast-proliferative populations. These insights may have considerable impact on therapy selection and response in breast cancer patients.
- Published
- 2021
- Full Text
- View/download PDF
50. Hypoxia Triggers the Intravasation of Clustered Circulating Tumor Cells.
- Author
-
Donato C, Kunz L, Castro-Giner F, Paasinen-Sohns A, Strittmatter K, Szczerba BM, Scherrer R, Di Maggio N, Heusermann W, Biehlmaier O, Beisel C, Vetter M, Rochlitz C, Weber WP, Banfi A, Schroeder T, and Aceto N
- Subjects
- Animals, Female, Humans, Male, Mice, Cell Hypoxia immunology, Neoplastic Cells, Circulating immunology, Proteomics methods
- Abstract
Circulating tumor cells (CTCs) are shed from solid cancers in the form of single or clustered cells, and the latter display an extraordinary ability to initiate metastasis. Yet, the biological phenomena that trigger the shedding of CTC clusters from a primary cancerous lesion are poorly understood. Here, when dynamically labeling breast cancer cells along cancer progression, we observe that the majority of CTC clusters are undergoing hypoxia, while single CTCs are largely normoxic. Strikingly, we find that vascular endothelial growth factor (VEGF) targeting leads to primary tumor shrinkage, but it increases intra-tumor hypoxia, resulting in a higher CTC cluster shedding rate and metastasis formation. Conversely, pro-angiogenic treatment increases primary tumor size, yet it dramatically suppresses the formation of CTC clusters and metastasis. Thus, intra-tumor hypoxia leads to the formation of clustered CTCs with high metastatic ability, and a pro-angiogenic therapy suppresses metastasis formation through prevention of CTC cluster generation., Competing Interests: Declaration of Interests N.A. and C.D. are listed as inventors in patent application EP 19188215.8, “Angiogenesis promoting agents for prevention of metastatic cancer.” N.A. is a paid consultant for companies with an interest in liquid biopsy., (Copyright © 2020 The Author(s). Published by Elsevier Inc. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.